Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … to progress its other pipeline candidates, to advance its RNA-editing technology platforms, and for working capital and …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business Operations and … ® EONs are designed to recruit an endogenously expressed RNAediting system called ADAR, which can direct the change …